• Explore /
  • Poster
  • / RELATIVITY-123: A phase 3, randomized, open-label study of nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) versus regorafenib or trifluridine + tipiracil (TAS-102) in later-line metastatic colorectal cancer (mCRC).

RELATIVITY-123: A phase 3, randomized, open-label study of nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) versus regorafenib or trifluridine + tipiracil (TAS-102) in later-line metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

null

Kynan Feeney

St. John of God Murdoch Hospital, Perth, Australia;

Kynan Feeney , Warren Lance Joubert , Rodolfo Eduardo Bordoni , Sunil Babu , Sathiya Marimuthu , Bill Hipkin , Liping Huang , Rachel Tam , Mirelis Acosta Rivera

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05328908

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS278)

DOI

10.1200/JCO.2023.41.4_suppl.TPS278

Abstract #

TPS278

Poster Bd #

P20

Abstract Disclosures

Similar Posters

First Author: Gerard Zalcman

First Author: Yelena Yuriy Janjigian

First Author: Timothy Jay Price

First Author: Samuel J Klempner